Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clair Beard, M.D.

Co-Author

This page shows the publications co-authored by Clair Beard and Quoc-Dien Trinh.
Connection Strength

1.569
  1. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e96-e97.
    View in: PubMed
    Score: 0.196
  2. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e100-e101.
    View in: PubMed
    Score: 0.193
  3. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol. 2018 02; 73(2):262-270.
    View in: PubMed
    Score: 0.189
  4. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523.
    View in: PubMed
    Score: 0.050
  5. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76.
    View in: PubMed
    Score: 0.047
  6. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
    View in: PubMed
    Score: 0.047
  7. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
    View in: PubMed
    Score: 0.045
  8. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
    View in: PubMed
    Score: 0.044
  9. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
    View in: PubMed
    Score: 0.044
  10. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8.
    View in: PubMed
    Score: 0.043
  11. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
    View in: PubMed
    Score: 0.042
  12. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
    View in: PubMed
    Score: 0.042
  13. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
    View in: PubMed
    Score: 0.042
  14. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
    View in: PubMed
    Score: 0.041
  15. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
    View in: PubMed
    Score: 0.041
  16. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
    View in: PubMed
    Score: 0.040
  17. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
    View in: PubMed
    Score: 0.040
  18. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
    View in: PubMed
    Score: 0.039
  19. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
    View in: PubMed
    Score: 0.039
  20. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
    View in: PubMed
    Score: 0.039
  21. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
    View in: PubMed
    Score: 0.039
  22. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
    View in: PubMed
    Score: 0.038
  23. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
    View in: PubMed
    Score: 0.038
  24. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
    View in: PubMed
    Score: 0.038
  25. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
    View in: PubMed
    Score: 0.038
  26. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
    View in: PubMed
    Score: 0.038
  27. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.